A thorough QT/QTc study of clinical and supra-therapeutic doses of preladenant in volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2013
Price : $35 *
At a glance
- Drugs Preladenant (Primary) ; Moxifloxacin
- Indications Parkinson's disease
- Focus Adverse reactions
- 24 Jul 2013 New trial record
- 16 Jul 2013 Results published in the European Journal of Clinical Pharmacology.